Exploring gaps in GLP-1 research, care, and coverage

Healthcare Strategies

A tartalmat a Xtelligent Healthcare Media biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Xtelligent Healthcare Media vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

1M ago 16:35

MP3•Epizód kép

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

The significant progress made in GLP-1 research, care delivery, and insurance coverage
Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

120 epizódok

#Business #Healthcare Strategies #Xtelligent Healthcare Media